Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Subunit |
Clinical data | |
Trade names | Covovax, [1] Nuvaxovid [2] [3] [4] |
Other names | |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category | |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank | |
UNII | |
KEGG |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). [29]
The Novavax COVID‑19 vaccine is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2. [4]
This section needs to be updated.(December 2023) |
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [30] Efficacy is closely related to effectiveness, which is generally expected to slowly decrease over time. [31]
In December 2021, Novavax reported that its phase III trial showed the vaccine achieved its primary endpoint of preventing infection at least seven days after the second dose. [32] Overall efficacy against different SARS-CoV-2s was 90.4% and efficacy against moderate-to-severe disease was 100%. [33] [32] Trials were conducted before the emergence of the SARS-CoV-2 Omicron variant, which has sharply reduced the effectiveness of authorized vaccines in preventing infections. [34]
Doses | Severity of illness | Omicron | Delta | Alpha | Gamma | Beta | Others circulating previously |
---|---|---|---|---|---|---|---|
1 | Symptomatic | Not reported | Not reported | 83% (74–90%) [lower-alpha 1] | Not reported | Not reported | 83% (74–90%) [lower-alpha 1] |
Hospitalization | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | |
2 | Symptomatic | Not reported | Not reported | 86% (71–94%) [35] | Not reported | 51% (−1 to 76%) [36] | 96% (74–99%) [lower-alpha 1] |
Hospitalization | Not reported | Not reported | 100% [lower-alpha 2] [35] | Not reported | Not reported | 100% [lower-alpha 2] [lower-alpha 1] |
The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell. [4]
Additional possible side effects include anaphylaxis (severe allergic reaction), paresthesia (unusual feeling in the skin, such as tingling or a crawling sensation) and hypoesthesia (decreased feeling or sensitivity, especially in the skin), and pericarditis (inflammation of lining around the heart). [37] It has also been reported that myocarditis (inflammation of heart muscle cells) as reported incidence from receiving the NVX-CoV2373 vaccine. [38] [39]
On 27 January 2023, Australia's Therapeutic Goods Administration indicated it will add tinnitus to its label. [40]
The vaccine requires two doses [41] and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures. [42] The second dose can be administered three to eight weeks apart from the first dose. [43] The vaccine injection can be administered intramuscularly (ie. deltoid, upper thigh, or upper buttock). There are currently no drug interaction that may affect the vaccine's efficacy if administered with other vaccines at the same time. [43]
It is recommended that pregnant individuals, and those planning to get pregnant in the future, to get their COVID-19 vaccines updated . The vaccine is a recombinant protein, not a live virus, therefore it will not replicate and spread to the infant. [44] The patient should weigh the potential risks and complications if they decided to not get the virus due to insufficient data in pregnancy compared to being vaccinated for protection against the SARS-CoV-2 infection.
There are no studies conducted to trial the efficacy and safety of Novovax vaccine to patients who are breastfeeding. Since Novavax is not a live virus, it can be extrapolated that the vaccine will not replicate and concentrate in the breast milk. [44]
NVX-CoV2373 has been described as both a protein subunit vaccine [45] [46] and a virus-like particle vaccine, [47] [48] though the producers call it a "recombinant nanoparticle vaccine". [49] By engineering the nanoparticle to contain the virus spike protein as the antigen, it allows the immune cells to easily recognize the antigen as the target protein. [50]
The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. [51] The spike protein was modified by incorporating two proline amino acids in order to stabilize the pre-fusion form of the protein; this same 2P modification is being used in several other COVID‑19 vaccines. [52] The baculovirus is made to infect a culture of Sf9 moth cells, which then create the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins. [45] [46] [49]
The formulation includes a saponin-based adjuvant [45] [46] [49] named Matrix-M.
Matrix-M adjuvant source is purified from Quillaja Saponaria Molina Tree. Matrix-M adjuvant is combined with the spike protein from the SARS-CoV-2 antigen to induce immune response in body upon vaccination. The adjuvant primarily enhances local antibodies and immunity at the local site of injection and draining lymph nodes. The adjuvant demonstrates its protection against the virus by inducing innate immune system rapidly. At the local site of injection, the adjuvant recruits antigen presenting cells and attracts more T cells, such as CD4+ and CD8+ T cells. [38] After entry of the vaccine nanoparticle containing the recombinant spike protein of the virus, it binds to ACE2 (angiotensin-converting enzyme 2) receptor to allow endocytosis and viral replication. However, upon endocytosis these viral particles are digested by lysosome and presented to MHC class molecules. This will lead to attracting T cells (CD4+ and CD8+). [53] This chemokine activity is further enhanced by the presence of the adjuvant component to enhance immune response from the viral particle. The cascade of immune activation leads to immediate immune response to target the virus as well as creating memory B cells specific to the antigen that the virus have. [38] These memory B cells enhances our immune response by faster immune cell recognition of these subsequent viral exposure to the same antigen compared to the initial exposure. [53]
In February 2021, Novavax partnered with Takeda to manufacture the vaccine in Japan, where its COVID‑19 vaccine candidate is known as TAK-019. [54]
Novavax signed an agreement with Serum Institute of India for mass scale production for developing and low-income countries. [55] In 2020 it was reported, that the vaccine would be manufactured in Spain [56] and in November 2021 it was reported to be produced in Poland by the Mabion company. [57] As of 2021, antigens were made at Novavax's factory Novavax CZ in the Czech Republic; [58] Novavax CZ was also marketing authorisation holder of its EU authorization. [4]
In May 2021, Serum Institute of India said that it started the production of the Novavax COVID‑19 vaccine candidate branded as Covovax in India after receiving permission from the Indian government. [59]
In January 2020, Novavax announced development of a vaccine candidate, codenamed NVX-CoV2373, to establish immunity to SARS-CoV-2. [60] Novavax's work is in competition for vaccine development among dozens of other companies. [61]
In March 2020, Novavax announced a collaboration with Emergent BioSolutions for preclinical and early-stage human research on the vaccine candidate. [62] Under the partnership, Emergent BioSolutions was supposed to manufacture the vaccine at large scale at their Baltimore facility. [63] However, following production issues with the Johnson & Johnson and Oxford–AstraZeneca vaccines at its Baltimore plant and to decrease the burden on the plant, Novavax subsequently partnered with a different manufacturer in a new agreement overseen by the U.S. government. [64]
Trials have also taken place in the United Kingdom. [65] [66] The first human safety studies of the candidate, codenamed NVX-CoV2373, started in May 2020 in Australia. [67] [68]
In July 2020, the company announced it might receive US$1.6 billion from Operation Warp Speed to expedite development of its coronavirus vaccine candidate by 2021 –if clinical trials show the vaccine to be effective. [69] [70] A spokesperson for Novavax stated that the $1.6 billion was coming from a "collaboration" between the Department of Health and Human Services and Department of Defense. [69] [70]
In May 2020, Australia's first human trials of a candidate COVID‑19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. It involved about 130 volunteers aged between 18-59. [71]
In September 2020, Novavax started for a phase III trial with 15,000 in the UK. [72] [73]
In December 2020 Novavax started the PREVENT-19 (NCT04611802) phase III trial in the US and Mexico, funded by NIAID and BARDA. [74] [75]
In May 2021, Novavax initiated a pediatric expansion for the phase III clinical trial, with 3,000 adolescents 12–17 years of age in up to 75 sites in the United States. [76]
In January 2021, Novavax reported that preliminary results from the United Kingdom trial showed that its vaccine candidate was more than 89% effective. [77] [42]
In June 2021, a primary Novavax-funded study found that the vaccine has an overall efficacy of 83.4% two weeks after the first dose and 89.7% one week after the second dose. [35] A post hoc analysis showed an efficacy of 86.3% against the B.1.1.7 (Alpha) variant and 96.4% against "non-B.1.1.7 strains", the majority of which were the "prototype strains" (original strain). [35] [78]
In January 2021, Novavax reported that interim results from a trial in South Africa showed a lower effectiveness rate against the Beta variant (lineage B.1.351), at around 50–60%. [41] [79]
In a study reported in March and May 2021, the efficacy of the Novavax vaccine (NVX-CoV2373) was tested in a preliminary randomized, placebo-controlled study involving 2684 participants who were negative for COVID at baseline testing. The Beta variant was the predominant variant to occur, with post-hoc analysis indicating a cross-protective vaccine efficacy of Novavax against Beta of 51.0% for HIV-negative participants. [51] [80] [81]
In June 2021, Novavax announced overall 90.4% efficacy in the phase III US & Mexico trial that involved nearly 30,000 people aged 18 years of age and older. [82] From the total 77 COVID-19 cases found in the trial participants, 14 occurred in the vaccine group, while 63 occurred in the placebo group. [83]
About 216,000 doses of the Novavax COVID-19 vaccine were administered in the EU/EEA from authorization to 26 June 2022. [37]
|
In February 2021, the European Medicines Agency (EMA) started a rolling review of the Novavax COVID-19 vaccine (NVX‑CoV2373). [5] In November 2021, the EMA received application for conditional marketing authorization. [84] In December 2021, the European Commission granted a conditional marketing authorization across the EU, following a recommendation from the EMA, for it to be sold under the brand name Nuvaxovid. [85] [4] [86] [87]
As of November 2021, it has been authorized for use in Indonesia, [88] the Philippines, [89] as of December in India, [90] as of January 2022 in South Korea, [91] [92] Australia, [93] [94] as of February 2022 in the United Kingdom, [95] Canada, [96] Taiwan, [97] and Singapore. [98] [99] As of December 2021 it was validated by the World Health Organization. [100]
In June 2022, the FDA's advisory committee voted 21-0 with one abstention to recommend authorization of Novavax's vaccine for use in adults in the United States. [101] [102] In July 2022, the FDA authorized NVX-CoV2373 for emergency use as a primary immunization (not booster) in adults. [103] [24] making it the fourth COVID‑19 vaccine authorized in the US. [34] In July 2022, the US Centers for Disease Control and Prevention (CDC) recommended the Novavax COVID‑19 vaccine as a two-dose primary series for adults age 18 and older, thus endorsing the recommendation from the Advisory Committee on Immunization Practices (ACIP) regarding this vaccine. [104] [105] In August 2022, the FDA granted Emergency Use Authorization for the Novavax COVID‑19 vaccine in people aged 12–17 years. [27] In August 2022, the CDC recommended the Novavax COVID‑19 vaccine for adolescents aged 12–17 years. [106]
In October 2023, the FDA amended the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the Novavax COVID-19 Vaccine, Adjuvanted (2023–2024 Formula) and removed the authorization for the Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent). [107] [108]
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus.
COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in humans to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) that encodes a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial guidance recommended a two-dose regimen, given 21 days apart; this interval was subsequently extended to up to 42 days in the United States, and up to four months in Canada.
The Janssen COVID‑19 vaccine, sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.
CoVLP was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.
SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.
The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.
The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.
Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, It is South Korea's first homegrown COVID-19 vaccine and utilizes GSK's AS03 adjuvant technology.
Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:
Matrix-M is a vaccine adjuvant, a substance that is added to various vaccines to stimulate the immune response. It was patented in 2020 by Novavax and is composed of nanoparticles from saponins extracted from Quillaja saponaria (soapbark) trees, cholesterol, and phospholipids. It is an immune stimulating complex (ISCOM), which are nanospheres formed when saponin is mixed with two types of fats.
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.